

Personalised tumor vaccines keep cancer in check

LONDON, UNITED KINGDOM, June 13, 2017 /EINPresswire.com/ -- Throughout the last decade, novel cancer therapeutics has seen tremendous developments, through targeting tumor cell-intrinsic pathways, as well as targeting tumor cell-extrinsic factors such as growth factors.



Notable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T-cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies. This creates the need for effective means of expanding the T-cells in patients using [cancer vaccines](#), which will be further explored by MSD, Exicure, Genentech and INSERM.

There has been substantial progress made in these fields and It's time to connect these fields to enable the linking of genetic alterations with the type of immune response. SMi's 6th annual Cancer Vaccines conference will host high level cancer geneticists, cancer biologists, experts in cancer antigen, tumor immunologists and vaccinologists, to discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigens and T-cell biology might enable development of next-generation novel therapies for patients with cancer.

With the increasing use of various [immunotherapy](#) strategies in the clinic, it is essential for immunomonitoring techniques to be conducted to follow the response of patients to therapy. Such investigations will enable the discovery of neoantigens that may contribute to the efficacy of treatment. The potential cellular players, the use of screening techniques to monitor effects of treatment and an account of an immunotherapy trial will illustrate what is possible in clinical practice.

The Biomarkers of immune response workshop is aimed at both clinical and research investigators to give insights into how to develop tools for both developing new therapeutic strategies and how to monitor responses to treatment. This will enable you to design clinical trials and to set up laboratory investigations to evaluate response to immunotherapy.

There is currently an £200 early bird discount for all registrations made before June 30th 2017. For more registration details please visit www.cancervaccineevent.com/ein

6th annual Cancer Vaccines Conference
27th – 28th September 2017
London, UK

www.cancervaccineevent.com/ein

Follow the conversation on Twitter and LinkedIn at #cancervac17

Kyra Williams

SMi Group Ltd
+44 (0)20 7827 6012
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.